CN115996728A - 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 - Google Patents
利用Rho激酶抑制剂治疗阿尔茨海默病的方法 Download PDFInfo
- Publication number
- CN115996728A CN115996728A CN202180043725.7A CN202180043725A CN115996728A CN 115996728 A CN115996728 A CN 115996728A CN 202180043725 A CN202180043725 A CN 202180043725A CN 115996728 A CN115996728 A CN 115996728A
- Authority
- CN
- China
- Prior art keywords
- patients
- fasudil
- disease
- alzheimer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014272P | 2020-04-23 | 2020-04-23 | |
| US63/014272 | 2020-04-23 | ||
| PCT/US2021/012588 WO2021216139A1 (en) | 2020-04-23 | 2021-01-08 | Methods of using rho kinase inhibitors to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115996728A true CN115996728A (zh) | 2023-04-21 |
Family
ID=78269840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180043725.7A Pending CN115996728A (zh) | 2020-04-23 | 2021-01-08 | 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12329761B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138842A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023523706A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115996728A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175183A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012957A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021216139A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11642352B2 (en) * | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| CN115998736B (zh) * | 2023-03-28 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | Y-27632在特异性抑制幻觉作用中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| US20060212090A1 (en) * | 2005-03-01 | 2006-09-21 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
| EP2061314A4 (en) * | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20110237600A1 (en) * | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| EP2825175B1 (en) * | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017003466A1 (en) * | 2015-06-30 | 2017-01-05 | University Of South Florida | Conversion of non-neuronal cells into neurons |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US11642352B2 (en) | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| US11311553B1 (en) | 2020-10-22 | 2022-04-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| WO2023097151A1 (en) * | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
-
2021
- 2021-01-08 US US17/996,812 patent/US12329761B2/en active Active
- 2021-01-08 JP JP2022563366A patent/JP2023523706A/ja active Pending
- 2021-01-08 CA CA3175183A patent/CA3175183A1/en active Pending
- 2021-01-08 EP EP21793029.6A patent/EP4138842A4/en active Pending
- 2021-01-08 CN CN202180043725.7A patent/CN115996728A/zh active Pending
- 2021-01-08 WO PCT/US2021/012588 patent/WO2021216139A1/en not_active Ceased
- 2021-01-08 MX MX2022012957A patent/MX2022012957A/es unknown
-
2023
- 2023-02-28 US US18/175,605 patent/US11771704B1/en active Active
-
2025
- 2025-05-13 US US19/206,355 patent/US20250268911A1/en active Pending
- 2025-12-25 JP JP2025282162A patent/JP2026053635A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230302011A1 (en) | 2023-09-28 |
| MX2022012957A (es) | 2022-11-09 |
| EP4138842A1 (en) | 2023-03-01 |
| CA3175183A1 (en) | 2021-10-28 |
| US20230190765A1 (en) | 2023-06-22 |
| EP4138842A4 (en) | 2024-04-24 |
| JP2026053635A (ja) | 2026-03-25 |
| US12329761B2 (en) | 2025-06-17 |
| JP2023523706A (ja) | 2023-06-07 |
| US11771704B1 (en) | 2023-10-03 |
| US20250268911A1 (en) | 2025-08-28 |
| WO2021216139A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11771704B1 (en) | Methods of using rho kinase inhibitors to treat alzheimer's disease | |
| US11642352B2 (en) | Methods of treating wandering in Lewy dody dementia | |
| CN116249532A (zh) | 使用Rho激酶抑制剂治疗血管性痴呆的方法 | |
| US11666583B2 (en) | Methods of treating cortical dementia associated wandering | |
| US20230263806A1 (en) | Methods of treating proteinopathies | |
| EP4125910B1 (en) | Rho kinase inhibitors for treating frontotemporal dementia | |
| WO2022046158A1 (en) | Methods of treating age-related cognitive decline | |
| EP4203961A1 (en) | Methods of treating age-related cognitive decline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |